source
- Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitPlus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…
- K2 Therapeutics seeks to blend China’s speed with global expertise after winning Endpoints 2026 awardK2 Therapeutics, a small drug development company, was named the winner of the Endpoints 2026 award. The company said it will try to combine the rapid development pace found in China with its own…